Kidney Disease and Proteinuria
Travere Therapeutics Inc. supports research in proteinuric glomerular diseases, with emphasis on focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), IgA nephropathy (IgAN), IgA vasculitis (IgAV), and Alport syndrome. Its studies focus on renal protection, reduction of proteinuria, and preservation of kidney function.
- FSGS
- IgA nephropathy
- Alport syndrome
Research activity in this area reflects a strong therapeutic interest in chronic glomerular disease and related kidney injury.
Rare Renal Disorders in Pediatric and Adult Populations
The sponsor funds clinical research across both pediatric and adult patients with selected kidney diseases, including conditions marked by persistent proteinuria and progressive loss of renal function. These studies address treatment needs in uncommon nephrology populations.
- Pediatric kidney disease
- Renal function preservation
- Proteinuria control
This area includes ongoing interest in renal disorders where long-term management is central to clinical care.
Classical Homocystinuria
Travere Therapeutics Inc. also funds research in classical homocystinuria (HCU), a rare inherited metabolic disorder associated with elevated homocysteine and methionine levels. The therapeutic focus includes biochemical control and treatment options for patients receiving standard care.
- Homocystinuria
- Homocysteine metabolism
- Inherited metabolic disease
Clinical activity in this field centers on rare disease management and metabolic correction.
